This Article Abstract Full Text (PDF) All Versions of this Article: 107/13/1733    most recent 01.CIR.0000057982.50167.6Ev1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vakkilainen, J. Search for Related Content PubMed PubMed Citation Articles by Vakkilainen, J. Related Collections Lipids Risk Factors Type 2 diabetes Angiography

(Circulation. 2003;107:1733.)
© 2003 American Heart Association, Inc.

Clinical Investigation and Reports

Relationships Between Low-Density Lipoprotein Particle Size, Plasma Lipoproteins, and Progression of Coronary Artery Disease

The Diabetes Atherosclerosis Intervention Study (DAIS)

Juha Vakkilainen, MD; George Steiner, MD; Jean-Claude Ansquer, MD; Francois Aubin, MD; Stephanie Rattier, MSc; Christelle Foucher, PhD; Anders Hamsten, MD; Marja-Riitta Taskinen, MD, on behalf of the DAIS Group

From the Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland (J.V., M.-R.T.); the University Health Network, Toronto, Canada (G.S.); Laboratories Fournier, Daix, France (J.-C.A., F.A., S.R., C.F.); and the Atherosclerosis Research Unit, King Gustaf V Research Institute, Karolinska Hospital, Stockholm, Sweden (A.H.).

Correspondence to Professor Marja-Riitta Taskinen, Biomedicum Helsinki, Haartmaninkatu 8, PO Box 700, 00029 HUS, Helsinki, Finland. E-mail mataskin{at}helsinki.fi

	Abstract

Top Abstract Introduction Methods Results Discussion References

 
Background— The Diabetes Atherosclerosis Intervention Study showed that treatment with fenofibrate decreases progression of coronary atherosclerosis in subjects with type 2 diabetes. We determined whether on-treatment plasma lipid concentrations and LDL particle size contribute to the favorable effect of fenofibrate on the progression of coronary artery disease (CAD).

Methods and Results— A total of 418 subjects with type 2 diabetes were randomly assigned to 200 mg micronized fenofibrate daily or placebo. The mean follow-up time was 39.6 months. LDL peak particle diameter (LDL size) was determined by polyacrylamide gradient gel electrophoresis from 405 subjects at baseline and at the end of the study. Progression of CAD was measured with quantitative coronary angiography. LDL size increased significantly more in the fenofibrate group than in the placebo group (0.98±1.04 versus 0.32±0.92 nm, P<0.001). In the combined group, small LDL size was significantly associated with progression of CAD measured as the increase of percentage diameter stenosis (r=-0.16, P=0.002) and decreases in minimum (r=-0.11, P=0.030) and mean (r=-0.10, P=0.045) lumen diameter. High on-treatment LDL cholesterol, apolipoprotein B, and triglyceride concentrations were also associated with the progression of CAD. In regression analyses, small LDL size added to the effect of LDL cholesterol and apolipoprotein B on the progression of CAD. Similar associations were observed in the fenofibrate group, whereas in the placebo group, lipoprotein variables were not significantly correlated with the progression of CAD.

Conclusions— Changes in LDL size and plasma lipid levels account for part of the antiatherogenic effect of fenofibrate in type 2 diabetes.

Key Words: coronary disease • fenofibrate • diabetes mellitus • lipoproteins • angiography

	Introduction

Top Abstract Introduction Methods Results Discussion References

 
Cardiovascular disease is the major cause of death in diabetic patients, and the risk of cardiovascular morbidity and mortality is significantly higher in subjects with diabetes compared with nondiabetic subjects.¹ Hypercholesterolemia, hypertension, and other traditional risk factors of atherosclerosis are also important in diabetic patients, but they do not explain the excess risk in diabetes. Hypertriglyceridemia, low HDL cholesterol (HDL-C), and a preponderance of small LDL particles are typical features of dyslipidemia in subjects with type 2 diabetes. Several cross-sectional and prospective studies have linked small, dense LDL to coronary artery disease (CAD).^2–5 However, small LDL particles are associated with other metabolic disturbances, and their significance in atherogenesis is still under debate.

In the Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT), treatment with gemfibrozil significantly reduced recurrence of CAD events without a significant reduction in serum LDL cholesterol (LDL-C) concentration.⁶ Further analyses have suggested that although the beneficial effects of gemfibrozil in VA-HIT were significantly associated with an increase in HDL-C, only a portion of this benefit could be explained by changes in total HDL-C concentration or other traditional lipid parameters.⁷ The results of the Diabetes Atherosclerosis Intervention Study (DAIS) showed that fenofibrate treatment is associated with significantly less progression of focal CAD (40% less progression of minimum lumen diameter versus placebo treatment, P=0.029; 42% less progression in percentage diameter stenosis versus placebo treatment, P=0.02) and improved the plasma lipid profile in subjects with type 2 diabetes.⁸ Fenofibrate causes a shift toward larger, more buoyant LDL particles,^9,10 which is a potentially antiatherogenic change. Therefore, we examined whether changes in LDL particle size may contribute to the favorable effect of fenofibrate on CAD progression in DAIS participants.

	Methods

Top Abstract Introduction Methods Results Discussion References

 
Subject inclusion and exclusion criteria have been described.¹¹ Briefly, patients were men and women with type 2 diabetes, 40 to 65 years old, with or without previous coronary intervention (coronary artery bypass grafting or percutaneous transluminal coronary angioplasty). The lipid entry criteria were a total cholesterol/HDL-C ratio of 4, plus either LDL-C 3.5 to 4.5 mmol/L and triglyceride concentration of 5.2 mmol/L, or a triglyceride concentration of 1.7 to 5.2 mmol/L and LDL-C 4.5 mmol/L. Each physician was allowed to adjust the glucose-lowering treatment to optimize metabolic control in the individual participant. Eligible patients were randomly assigned to micronized fenofibrate or placebo for 3 years.⁸ The average time between baseline and final angiograms was 39.6 months. Progression of coronary artery atherosclerosis was analyzed by quantitative angiograms as described.⁸ The study was approved by local ethics committees, and all participants gave their informed consent.

Of the 418 patients randomized, 405 (207 placebo, 198 fenofibrate) patients had LDL size measurements at baseline and either at the end of the study or after 1 year of treatment. Of the 405 patients, 379 had a final angiogram. For the 26 (12 placebo, 14 fenofibrate) patients with a missing final angiogram, "worst-case" imputed angiographic parameters were used as described to permit analysis by intention to treat.⁸ Two subjects in the fenofibrate group and 4 subjects in the placebo group were excluded from analyses that required on-treatment plasma apolipoprotein B (apoB) levels because of missing data.

Biochemical Analyses
Plasma total and HDL-C, total triglycerides, and apoB were measured as described.¹² LDL-C was determined by the Friedewald formula.¹³ LDL peak particle diameter (LDL size) was measured from serum samples with polyacrylamide gradient gel electrophoresis as described,¹⁴ with slight modifications. Specifically, gels were stained with Coomassie brilliant blue protein stain instead of Sudan black lipid stain. All available values during the treatment period were used to calculate mean on-treatment lipid levels. For the LDL size, only the baseline and 1 on-treatment value (obtained at the end of the study and referred to as "final LDL size") were available. Because plasma triglyceride level is the major determinant of LDL size and the effect of fenofibrate on triglyceride levels was stable during the whole treatment period, it is likely that the final LDL size is a good measure of mean on-treatment LDL size.

Statistical Analyses
The between-groups comparison of on-treatment lipid parameters and final LDL size was performed by use of ANCOVA with baseline value, center, sex, and history of previous coronary intervention as covariates. Pearson’s correlation coefficients were used to analyze associations between absolute changes in LDL size and other lipoprotein parameters and associations between mean on-treatment lipids or final LDL size and absolute changes in angiographic variables. Absolute changes in percentage diameter stenosis are presented according to tertiles of final LDL size and mean on-treatment lipid concentrations for illustrative purposes (Figure). R² and probability values are provided for multivariate regression analysis on changes in percentage diameter stenosis versus on-treatment lipid parameters and final LDL size, which were used as continuous variables. Plasma triglycerides were logarithmically transformed before the analyses. Results are given as mean±SD. All statistical analyses were done with SAS software (version 8.1). A probability value of P<0.05 was considered statistically significant.

View larger version (29K): [in this window] [in a new window]   The participants (n=405) divided into tertiles of mean on-treatment lipoproteins and final LDL size. The greatest progression of coronary atherosclerosis was observed in subjects with small LDL particles and highest LDL-C, apoB, and triglyceride (TG) levels. Left, Mean changes in percentage diameter stenosis according to tertiles of final LDL size and mean on-treatment LDL-C concentrations. LDL size (nm): small tertile, <24.61; medium tertile, 24.61 to 26.03; large tertile, >26.03. LDL-C concentration (mmol/L): low tertile, <3.019; medium tertile, 3.019 to 3.646; high tertile, >3.646. Middle, Mean changes in percentage diameter stenosis according to tertiles of final LDL size and mean on-treatment apoB concentrations. LDL size (nm): small tertile, <24.61; medium tertile, 24.61 to 26.03; large tertile, >26.03. ApoB concentration (g/L): low tertile, <0.986; medium tertile, 0.986 to 1.170; high tertile, >1.170. Right, Mean changes in percentage diameter stenosis according to tertiles of final LDL size and mean on-treatment TG concentrations. LDL size (nm): small tertile, <24.61; medium tertile, 24.61 to 26.03; large tertile, >26.03. TG concentration (mmol/L): low tertile, <1.514; medium tertile, 1.514 to 2.218; high tertile, >2.218.

	Results

Top Abstract Introduction Methods Results Discussion References

 
Baseline characteristics are shown in Table 1. No significant differences in age, body mass index, supine systolic and diastolic blood pressure, fasting plasma glucose, and HbA_1c were observed between the placebo and fenofibrate groups. Fenofibrate did not have relevant effects on blood pressure or glycemic control, as described.⁸ Baseline and mean on-treatment lipid assessments are shown in Table 2. Fenofibrate treatment significantly increased LDL particle size and HDL-C concentration and decreased plasma triglycerides, total cholesterol, LDL-C, and apoB concentrations compared with placebo. The absolute change in LDL size was related to the plasma triglyceride concentration achieved by fenofibrate treatment. In subjects in the lowest tertile of on-treatment triglycerides (<1.275 mmol/L), the increase in LDL size was 1.19±0.93 nm, but in the highest tertile (>1.805 mmol/L), it was only 0.69±1.05 nm. In the combined group, the change in LDL size was significantly associated with changes in plasma triglycerides (r=-0.56, P<0.0001), HDL-C (r=0.34, P<0.0001), total cholesterol (r=-0.30, P<0.0001), apoB (r=-0.31, P<0.0001), and LDL-C/apoB ratio (r=0.29, P<0.0001) but not with the change in LDL-C concentration (r=-0.03). These associations were also observed when fenofibrate and placebo groups were analyzed separately (not shown).

View this table: [in this window] [in a new window]   TABLE 1. Baseline Characteristics

View this table: [in this window] [in a new window]   TABLE 2. Baseline and On-Treatment Lipids and Lipoproteins

The relationships between plasma lipoproteins and angiographic changes are shown in Table 3. In the combined group and in the fenofibrate group alone, the final LDL particle size was inversely correlated with the increase in percentage diameter stenosis and the decreases in mean and minimum lumen diameter, indicating that the greatest progression of atherosclerosis occurred in subjects with small LDL particles. On-treatment apoB, total and LDL-C, and triglyceride concentrations showed positive correlations with the angiographic changes, indicating that the greatest progression of atherosclerosis occurred in subjects with the highest levels of these lipoproteins. Interestingly, in the placebo group, on-treatment lipoproteins were not significantly associated with angiographic changes.

View this table: [in this window] [in a new window]   TABLE 3. Univariate Correlation Analyses Between On-Treatment Lipid Parameters and Progression of Coronary Atherosclerosis in Total, Fenofibrate, and Placebo Groups

We performed multivariate regression analyses to analyze the combined effects of LDL particle size and lipoprotein concentrations on the progression of coronary atherosclerosis (Table 4). Both on-treatment LDL-C concentration and final LDL particle size, as well as on-treatment apoB concentration and final LDL particle size, contributed significantly to the progression of CAD in the combined group. Addition of triglyceride and HDL-C did not significantly improve the model, which is probably explained by the intercorrelations between these variables and LDL size. These associations were a result of the changes observed in the fenofibrate group alone, whereas no such associations were observed in the placebo group.

View this table: [in this window] [in a new window]   TABLE 4. Multivariate Regression Analysis of the Change in Percentage Diameter Stenosis in Total (n=405), Fenofibrate (n=198), and Placebo (n=207) Groups

Progression of focal coronary atherosclerosis (increase in percentage diameter stenosis) in the combined group is illustrated in the Figure. The 405 subjects were divided into tertiles of mean on-treatment lipoproteins. The greatest deterioration was observed in patients with the highest LDL-C, apoB, and triglyceride levels. Importantly, LDL size modulated the progression of CAD so that subjects with small LDL particles had more progression of atherosclerosis than those with large LDL particles. Again, the effect of LDL size and other lipoproteins was because of the fenofibrate group alone and was not observed in the placebo group (not shown).

	Discussion

Top Abstract Introduction Methods Results Discussion References

 
The Diabetes Atherosclerosis Intervention Study was the first intervention trial that examined whether the correction of moderate dyslipidemia by fenofibrate reduces the progression of CAD in subjects with type 2 diabetes. The main result was that the subjects receiving fenofibrate had significantly less progression of focal atherosclerosis than the subjects receiving placebo.⁸ We have now investigated the effect of fenofibrate on LDL particle size and other components of diabetic dyslipidemia and their effect on CAD progression. Fenofibrate significantly increased LDL size and HDL-C concentration and decreased plasma triglyceride, total and LDL-C, and apoB concentrations. The on-treatment lipid values explained a significant but relatively small proportion of the changes in the coronary angiograms.

Two smaller angiography trials have examined the associations of small, dense LDL and progression of coronary atherosclerosis in subjects without diabetes. In the Familial Atherosclerosis Treatment Study, colestipol-lovastatin and colestipol-niacin treatments decreased hepatic lipase activity and increased LDL buoyancy. The increase in LDL buoyancy explained 37% of the variance in the change in coronary stenosis.¹⁵ In contrast, in the Bezafibrate Coronary Atherosclerosis Intervention Trial, on-trial LDL size was not correlated with the progression of atherosclerosis in coronary angiograms, whereas on-trial HDL₃ cholesterol and apoB explained a small proportion of the changes.¹⁶ In the present study, LDL size and plasma lipoprotein concentrations showed a statistically significant association with the progression of coronary atherosclerosis. In addition, we found support for the combined effect of small LDL particle size and other dyslipidemias on the progression of atherosclerosis. Notably, especially in subjects with low LDL-C or apoB levels, a preponderance of small, dense LDL particles increased the progression of coronary atherosclerosis. These results indicate that both the quality and the quantity of LDL modulate the development of atherosclerosis. Thus, focusing only on LDL-C concentration as a therapeutic target may be misleading in these subjects. Potential mechanisms for increased atherogenicity of small, dense LDL include enhanced inflow into the arterial wall,¹⁷ increased binding affinity to arterial wall proteoglycans,¹⁸ decreased binding affinity to the LDL receptor compared with mid-sized LDL particles,¹⁹ and increased susceptibility to oxidative modification.²⁰

Case-control studies with clinical end points have suggested that small LDL size is a risk factor for clinical CAD before but not after adjustment for other lipid variables.^3,4 In the Québec Cardiovascular Study, a prospective follow-up study of 2057 men, Lamarche et al⁵ recently showed that small LDL particles increase the probability of developing ischemic heart disease. The effect of small LDL was independent of other lipid and nonlipid risk factors and additive to the effects of high LDL-C and apoB level. To the best of our knowledge, our study shows for the first time that increasing LDL particle size and decreasing LDL-C and apoB levels by fenofibrate provides antiatherogenic benefit in subjects with type 2 diabetes and therefore extends the previous data. Further analysis of the Québec Cardiovascular Study data showed that the calculated cholesterol concentration in small LDL particles was superior to the LDL particle size in predicting the ischemic heart disease risk.²¹ Because we used protein and not lipid staining in measuring LDL size, we could not conduct a similar analysis. However, our finding that small LDL peak particle diameter (indicating increased proportion of small LDL particles) and LDL-C concentration have a combined effect in predicting the progression of coronary atherosclerosis supports the idea that both the amount and the quality of LDL-C are important risk factors for atherosclerosis. Interestingly, in the Cholesterol and Recurrent Events (CARE) trial, large LDL particle size at baseline was associated with increased risk of recurrence of coronary events in the placebo group but not in the pravastatin group.²² The participants of the CARE trial were survivors of myocardial infarction, but it is uncertain whether this could have an influence on the result.

We used quantitative coronary angiography to measure progression of atherosclerosis. The method has good reproducibility, and it was the accepted standard for the assessment of progression of CAD when DAIS was initiated.²³ The weaknesses of angiography include the fact that it visualizes only vessel lumen diameter and not the size of the atheroma in the vessel wall²⁴ and that vascular remodeling decreases its accuracy in measuring the progression of coronary atherosclerosis.²⁵ It is therefore likely that the actual associations between plasma lipoproteins and progression of atherosclerosis are stronger than those found by us and others.^16,26,27 The associations between plasma lipoprotein levels and progression of CAD were observed only in subjects assigned to fenofibrate but not in those assigned to placebo, which diluted the findings in the combined group. The data imply that significant changes in plasma lipoproteins must be obtained to decrease the progression of atherosclerosis. In a recent follow-up study, LDL-C and C-reactive protein, a marker of inflammation, had additive power in predicting future cardiovascular events.²⁸ Fibrates have antiinflammatory and plaque-stabilizing effects in addition to the lipid-lowering effect.²⁹ It is possible that these nonlipid actions increase the clinical benefit of fibrates even beyond the decreased progression of atherosclerosis that was detected in DAIS. Our preliminary data suggest, however, that fenofibrate did not significantly influence serum C-reactive protein levels (Hamsten et al, unpublished data). This implies that lipoprotein levels are more important than markers of inflammation in predicting the progression of atherosclerosis measured with angiography. The results of larger trials, such as the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial,³⁰ have to be awaited before the clinical benefit of the nonlipid actions of fibrates can be determined.

We conclude that treatment with fenofibrate has a favorable effect on the plasma lipid profile and reduces the progression of coronary atherosclerosis. Changes in LDL size and plasma lipid levels account for at least part of the beneficial action of fenofibrate. Small LDL particles increase the atherogenicity of hyperlipidemia in subjects with type 2 diabetes.

	Acknowledgments

 
This study was financed in part by Laboratories Fournier, the Helsinki University Central Hospital Research Foundation, the Biomedicum Research Foundation, and the Aarne and Aili Turunen Foundation. We thank Helinä Perttunen-Nio for the measurement of LDL particle sizes.

	Footnotes

 
The Diabetes Atherosclerosis Intervention Study was funded by an unrestricted grant from Laboratoires Fournier S.A., Daix, France, which manufactures fenofibrate. Drs Ansquer, Aubin, Rattier, and Foucher are full-time employees of Laboratoires Fournier S.A. Dr Taskinen has received honoraria for speaking engagements from Laboratoires Fournier S.A. Dr Steiner has received grant and research support from Abbott, Fournier, Merck, and AstraZeneca. The study was conducted independently by academic investigators.

Received November 11, 2002; revision received December 31, 2002; accepted January 7, 2003.

	References

Top Abstract Introduction Methods Results Discussion References

 

1. Morrish NJ, Wang SL, Stevens LK, et al. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia. 2001; 44: S14–S21.[CrossRef][Medline] [Order article via Infotrieve]
   
2. Austin MA, Breslow JL, Hennekens CH, et al. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA. 1988; 260: 1917–1921.[Abstract]
   
3. Stampfer MJ, Krauss RM, Ma J, et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA. 1996; 276: 882–888.[Abstract]
   
4. Gardner CD, Fortmann SP, Krauss RM. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA. 1996; 276: 875–881.[Abstract]
   
5. Lamarche B, St-Pierre AC, Ruel IL, et al. A prospective, population-based study of low density lipoprotein particle size as a risk factor for ischemic heart disease in men. Can J Cardiol. 2001; 17: 859–865.[Medline] [Order article via Infotrieve]
   
6. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999; 341: 410–418.[Abstract/Free Full Text]
   
7. Robins SJ, Collins D, Wittes JT, et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA. 2001; 285: 1585–1591.[Abstract/Free Full Text]
   
8. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet. 2001; 357: 905–910.[CrossRef][Medline] [Order article via Infotrieve]
   
9. Feher MD, Caslake M, Foxton J, et al. Atherogenic lipoprotein phenotype in type 2 diabetes: reversal with micronised fenofibrate. Diabetes Metab Res Rev. 1999; 15: 395–399.[CrossRef][Medline] [Order article via Infotrieve]
   
10. Vakkilainen J, Steiner G, Ansquer JC, et al. Fenofibrate lowers plasma triglycerides and increases LDL particle diameter in subjects with type 2 diabetes. Diabetes Care. 2002; 25: 627–628.[Free Full Text]
    
11. Steiner G. The Diabetes Atherosclerosis Intervention Study (DAIS): a study conducted in cooperation with the World Health Organization. The DAIS Project Group. Diabetologia. 1996; 39: 1655–1661.[CrossRef][Medline] [Order article via Infotrieve]
    
12. McGuinness C, Seccombe DW, Frohlich JJ, et al. Laboratory standardization of a large international clinical trial: the DAIS experience. DAIS Project Group, Diabetes Atherosclerosis Intervention Study. Clin Biochem. 2000; 33: 15–24.[CrossRef][Medline] [Order article via Infotrieve]
    
13. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972; 18: 499–502.[Abstract]
    
14. Vakkilainen J, Jauhiainen M, Ylitalo K, et al. LDL particle size in familial combined hyperlipidemia: effects of serum lipids, lipoprotein modifying enzymes and lipid transfer proteins. J Lipid Res. 2002; 43: 598–603.[Abstract/Free Full Text]
    
15. Zambon A, Hokanson JE, Brown BG, et al. Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density. Circulation. 1999; 99: 1959–1964.[Abstract/Free Full Text]
    
16. Ruotolo G, Ericsson CG, Tettamanti C, et al. Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). J Am Coll Cardiol. 1998; 32: 1648–1656.[Abstract/Free Full Text]
    
17. Björnheden T, Babyi A, Bondjers G, et al. Accumulation of lipoprotein fractions and subfractions in the arterial wall, determined in an in vitro perfusion system. Atherosclerosis. 1996; 123: 43–56.[CrossRef][Medline] [Order article via Infotrieve]
    
18. Anber V, Griffin BA, McConnell M, et al. Influence of plasma lipid and LDL-subfraction profile on the interaction between low density lipoprotein with human arterial wall proteoglycans. Atherosclerosis. 1996; 124: 261–271.[CrossRef][Medline] [Order article via Infotrieve]
    
19. Galeano NF, Milne R, Marcel YL, et al. Apoprotein B structure and receptor recognition of triglyceride-rich low density lipoprotein (LDL) is modified in small LDL but not in triglyceride-rich LDL of normal size. J Biol Chem. 1994; 269: 511–519.[Abstract/Free Full Text]
    
20. Chait A, Brazg RL, Tribble DL, et al. Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am J Med. 1993; 94: 350–356.[CrossRef][Medline] [Order article via Infotrieve]
    
21. St-Pierre AC, Ruel IL, Cantin B, et al. Comparison of various electrophoretic characteristics of LDL particles and their relationship to the risk of ischemic heart disease. Circulation. 2001; 104: 2295–2299.[Abstract/Free Full Text]
    
22. Campos H, Moye LA, Glasser SP, et al. Low-density lipoprotein size, pravastatin treatment, and coronary events. JAMA. 2001; 286: 1468–1474.[Abstract/Free Full Text]
    
23. McLaughlin PR, Gladstone P. Diabetes Atherosclerosis Intervention Study (DAIS): quantitative coronary angiographic analysis of coronary artery atherosclerosis. Cathet Cardiovasc Diagn. 1998; 44: 249–256.[CrossRef][Medline] [Order article via Infotrieve]
    
24. de Feyter PJ, Serruys PW, Davies MJ, et al. Quantitative coronary angiography to measure progression and regression of coronary atherosclerosis: value, limitations, and implications for clinical trials. Circulation. 1991; 84: 412–423.[Free Full Text]
    
25. Glagov S, Weisenberg E, Zarins CK, et al. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med. 1987; 316: 1371–1375.[Abstract]
    
26. Pitt B, Mancini GB, Ellis SG, et al. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. PLAC I Investigation. J Am Coll Cardiol. 1995; 26: 1133–1139.[Abstract]
    
27. Bestehorn HP, Rensing UF, Roskamm H, et al. The effect of simvastatin on progression of coronary artery disease. The Multicenter Coronary Intervention Study (CIS). Eur Heart J. 1997; 18: 226–234.[Abstract/Free Full Text]
    
28. Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002; 347: 1557–1565.[Abstract/Free Full Text]
    
29. Barbier O, Torra IP, Duguay Y, et al. Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol. 2002; 22: 717–726.[Abstract/Free Full Text]
    
30. Steiner G. Lipid intervention trials in diabetes. Diabetes Care. 2000; 23: B49–B53.[Medline] [Order article via Infotrieve]
    

This article has been cited by other articles:

				M. Adiels, S.-O. Olofsson, M.-R. Taskinen, and J. Boren Overproduction of Very Low-Density Lipoproteins Is the Hallmark of the Dyslipidemia in the Metabolic Syndrome Arterioscler. Thromb. Vasc. Biol., July 1, 2008; 28(7): 1225 - 1236. [Abstract] [Full Text] [PDF]

				B. J. Arsenault, I. Lemieux, J.-P. Despres, N. J. Wareham, R. Luben, J. J.P. Kastelein, K.-T. Khaw, and S. M. Boekholdt Cholesterol levels in small LDL particles predict the risk of coronary heart disease in the EPIC-Norfolk prospective population study Eur. Heart J., November 2, 2007; 28(22): 2770 - 2777. [Abstract] [Full Text] [PDF]

				V. Mallika, B. Goswami, and M. Rajappa Atherosclerosis Pathophysiology and the Role of Novel Risk Factors: A Clinicobiochemical Perspective Angiology, November 1, 2007; 58(5): 513 - 522. [Abstract] [PDF]

				J. O. Mudd, B. A. Borlaug, P. V. Johnston, B. G. Kral, R. Rouf, R. S. Blumenthal, and P. O. Kwiterovich Jr Beyond Low-Density Lipoprotein Cholesterol: Defining the Role of Low-Density Lipoprotein Heterogeneity in Coronary Artery Disease J. Am. Coll. Cardiol., October 30, 2007; 50(18): 1735 - 1741. [Abstract] [Full Text] [PDF]

				Y. Jang, O. Y. Kim, S. J. Koh, J. S. Chae, Y. G. Ko, J. Y. Kim, H. Cho, T.-S. Jeong, W. S. Lee, J. M. Ordovas, et al. The Val279Phe Variant of the Lipoprotein-Associated Phospholipase A2 Gene Is Associated with Catalytic Activities and Cardiovascular Disease in Korean Men J. Clin. Endocrinol. Metab., September 1, 2006; 91(9): 3521 - 3527. [Abstract] [Full Text] [PDF]

				A. Zambon, P. Gervois, P. Pauletto, J.-C. Fruchart, and B. Staels Modulation of Hepatic Inflammatory Risk Markers of Cardiovascular Diseases by PPAR-{alpha} Activators: Clinical and Experimental Evidence Arterioscler. Thromb. Vasc. Biol., May 1, 2006; 26(5): 977 - 986. [Abstract] [Full Text] [PDF]

				J. M. Tovar and D. B. Schering Management of Dyslipidemia in Special Populations Journal of Pharmacy Practice, April 1, 2006; 19(2): 63 - 78. [Abstract] [PDF]

				J. D. Otvos, D. Collins, D. S. Freedman, I. Shalaurova, E. J. Schaefer, J. R. McNamara, H. E. Bloomfield, and S. J. Robins Low-Density Lipoprotein and High-Density Lipoprotein Particle Subclasses Predict Coronary Events and Are Favorably Changed by Gemfibrozil Therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial Circulation, March 28, 2006; 113(12): 1556 - 1563. [Abstract] [Full Text] [PDF]

				M. Rizzo and K. Berneis Low-density lipoprotein size and cardiovascular risk assessment QJM, January 1, 2006; 99(1): 1 - 14. [Abstract] [Full Text] [PDF]

				M. Farnier, M. W. Freeman, G. Macdonell, I. Perevozskaya, M. J. Davies, Y. B. Mitchel, B. Gumbiner, and for the Ezetimibe Study Group Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia Eur. Heart J., May 1, 2005; 26(9): 897 - 905. [Abstract] [Full Text] [PDF]

				R. S. Birjmohun, B. A. Hutten, J. J.P. Kastelein, and E. S.G. Stroes Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: A meta-analysis of randomized controlled trials J. Am. Coll. Cardiol., January 18, 2005; 45(2): 185 - 197. [Abstract] [Full Text] [PDF]

				H. C. Geiss, S. Bremer, P. H. R. Barrett, C. Otto, and K. G. Parhofer In vivo metabolism of LDL subfractions in patients with heterozygous FH on statin therapy: rebound analysis of LDL subfractions after LDL apheresis J. Lipid Res., August 1, 2004; 45(8): 1459 - 1467. [Abstract] [Full Text] [PDF]

				R. Carmena, P. Duriez, and J.-C. Fruchart Atherogenic Lipoprotein Particles in Atherosclerosis Circulation, June 15, 2004; 109(23_suppl_1): III-2 - III-7. [Abstract] [Full Text]

				D. R. Witte, M. R. Taskinen, H. Perttunen-Nio, A. van Tol, S. Livingstone, and H. M. Colhoun Study of agreement between LDL size as measured by nuclear magnetic resonance and gradient gel electrophoresis J. Lipid Res., June 1, 2004; 45(6): 1069 - 1076. [Abstract] [Full Text] [PDF]

				R. M. Krauss Lipids and Lipoproteins in Patients With Type 2 Diabetes Diabetes Care, June 1, 2004; 27(6): 1496 - 1504. [Abstract] [Full Text] [PDF]

				T. Teerlink, P. G. Scheffer, S. J. L. Bakker, and R. J. Heine Combined data from LDL composition and size measurement are compatible with a discoid particle shape J. Lipid Res., May 1, 2004; 45(5): 954 - 966. [Abstract] [Full Text] [PDF]

				S. Alam, M. Stolinski, C. Pentecost, M. A. Boroujerdi, R. H. Jones, P. H. Sonksen, and A. M. Umpleby The Effect of a Six-Month Exercise Program on Very Low-Density Lipoprotein Apolipoprotein B Secretion in Type 2 Diabetes J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 688 - 694. [Abstract] [Full Text] [PDF]

				D. N. Muller, J. Theuer, E. Shagdarsuren, E. Kaergel, H. Honeck, J.-K. Park, M. Markovic, E. Barbosa-Sicard, R. Dechend, M. Wellner, et al. A Peroxisome Proliferator-Activated Receptor-{alpha} Activator Induces Renal CYP2C23 Activity and Protects from Angiotensin II-Induced Renal Injury Am. J. Pathol., February 1, 2004; 164(2): 521 - 532. [Abstract] [Full Text] [PDF]

				J. Frohlich and M. Dobiasova Fractional Esterification Rate of Cholesterol and Ratio of Triglycerides to HDL-Cholesterol Are Powerful Predictors of Positive Findings on Coronary Angiography Clin. Chem., November 1, 2003; 49(11): 1873 - 1880. [Abstract] [Full Text] [PDF]

				F. M. Sacks and H. Campos Low-Density Lipoprotein Size and Cardiovascular Disease: A Reappraisal J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 4525 - 4532. [Full Text] [PDF]

				A. D. Sniderman Non-HDL Cholesterol Versus Apolipoprotein B in Diabetic Dyslipoproteinemia: Alternatives and surrogates versus the real thing Diabetes Care, July 1, 2003; 26(7): 2207 - 2208. [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: 107/13/1733    most recent 01.CIR.0000057982.50167.6Ev1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vakkilainen, J. Search for Related Content PubMed PubMed Citation Articles by Vakkilainen, J. Related Collections Lipids